Comparative Pharmacology
Head-to-head clinical analysis: HEPTALAC versus LAX LYTE WITH FLAVOR PACKS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPTALAC versus LAX LYTE WITH FLAVOR PACKS.
HEPTALAC vs LAX-LYTE WITH FLAVOR PACKS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonia scavenger; lactulose is metabolized by colonic bacteria to organic acids, acidifying the colon, which converts NH3 to NH4+ and promotes ammonia excretion. Lactulose also reduces colonic transit time and bacterial production of ammonia.
Osmotic laxative: polyethylene glycol (PEG) retains water in the intestinal lumen, increasing stool volume and stimulating peristalsis. Electrolytes (sodium, potassium, chloride, bicarbonate) prevent electrolyte depletion.
Oral: 3.33 g (30 mL) 3 times daily. Rectal: 200 mL of 30% solution as retention enema, 3 times daily. Intravenous: 30 g as a single dose via intra-abdominal instillation.
Oral: 1 to 2 packets (4 to 8 g of polyethylene glycol 3350) dissolved in 4 to 8 ounces of water once daily, as needed for constipation. Maximum: 2 packets per day.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours in patients with normal hepatic function; prolonged in hepatic encephalopathy due to altered clearance (up to 24 hours).
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 20 hours).
Primarily renal (approximately 70-80%) as unchanged drug; minor biliary/fecal elimination (20-30%).
Primarily renal (30-50% unchanged) and biliary/fecal (50-70% as inactive metabolites).
Category C
Category C
Laxative
Laxative